<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103059</article-id><article-id pub-id-type="publisher-id">TCM-42802</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_26549894.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  慢性支气管炎急性发作期发病机制及药物治疗研究进展
  Research Progress on Pathogenesis and Drug Therapy in Acute Episode of Chronic Bronchitis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>尚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>屈</surname><given-names>金艳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>易</surname><given-names>小兰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>艳波</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>文</surname><given-names>复权</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>炜</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>湖南中医药大学，中药民族药物创新发展国际实验室，湖南 长沙</addr-line></aff><aff id="aff3"><addr-line>湖南安邦制药股份有限公司，湖南 长沙</addr-line></aff><aff id="aff2"><addr-line>湖南中医药大学，中药民族药物创新发展国际实验室，湖南 长沙；湖南安邦制药股份有限公司，湖南 长沙</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>420</fpage><lpage>426</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  慢性支气管炎是一种发病率高、病程长、易反复发作的疾病，且易发展成为慢性阻塞性肺疾病(COPD)，严重危害患者健康，因此采取适宜措施有效控制缓解慢性支气管炎的急性发作期具有十分重要的意义。在慢性支气管炎防治方面，中医药的优势和特色被临床认可，作者将对疾病急性发作期发病机制及药物治疗的最新进展进行分析、归纳总结，以期为该病的临床治疗提供更多依据和参考。
  Chronic bronchitis is a disease with high incidence, long course and easy to relapse, and can easily turn into COPD, which badly harms to patients’ health. Therefore, it is of great significance to take appropriate measures to effectively control and alleviate the acute episode of chronic bronchitis. In the field of bronchitis prevention and treatment, the advantages and characteristics of traditional Chinese medicine have been recognized clinically. In order to provide more evidences and references for the clinical treatment of the disease, the author will analyze and summarize the latest progress of the pathogenesis and the drug therapy of the disease in acute episode.
 
</p></abstract><kwd-group><kwd>慢性支气管炎，急性发作，发病机制，药物, Chronic Bronchitis</kwd><kwd> Acute Episode</kwd><kwd> Pathogenesis</kwd><kwd> Drug</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>慢性支气管炎是一种发病率高、病程长、易反复发作的疾病，且易发展成为慢性阻塞性肺疾病(COPD)，严重危害患者健康，因此采取适宜措施有效控制缓解慢性支气管炎的急性发作期具有十分重要的意义。在慢性支气管炎防治方面，中医药的优势和特色被临床认可，作者将对疾病急性发作期发病机制及药物治疗的最新进展进行分析、归纳总结，以期为该病的临床治疗提供更多依据和参考。</p></sec><sec id="s2"><title>关键词</title><p>慢性支气管炎，急性发作，发病机制，药物</p></sec><sec id="s3"><title>Research Progress on Pathogenesis and Drug Therapy in Acute Episode of Chronic Bronchitis</title><p>Shang Gao<sup>1,2</sup>, JinyanQu<sup>2</sup>, Xiaolan Yi<sup>2</sup>, Yanbo Li<sup>2</sup>, Fuquan Wen<sup>2</sup>, Wei Wang<sup>1*</sup></p><p><sup>1</sup>TCM and Ethnomedicine Innovation &amp; Development International Laboratory, Hunan University of Chinese Medicine, Changsha Hunan</p><p><sup>2</sup>Hunan Anbang Pharmaceutical Co., Ltd., Changsha Hunan</p><p><img src="//html.hanspub.org/file/20-2270679x5_hanspub.png" /></p><p>Received: Mar. 16<sup>th</sup>, 2021; accepted: May 21<sup>st</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/20-2270679x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Chronic bronchitis is a disease with high incidence, long course and easy to relapse, and can easily turn into COPD, which badly harms to patients’ health. Therefore, it is of great significance to take appropriate measures to effectively control and alleviate the acute episode of chronic bronchitis. In the field of bronchitis prevention and treatment, the advantages and characteristics of traditional Chinese medicine have been recognized clinically. In order to provide more evidences and references for the clinical treatment of the disease, the author will analyze and summarize the latest progress of the pathogenesis and the drug therapy of the disease in acute episode.</p><p>Keywords:Chronic Bronchitis, Acute Episode, Pathogenesis, Drug</p><disp-formula id="hanspub.42802-formula22"><graphic xlink:href="//html.hanspub.org/file/20-2270679x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/20-2270679x8_hanspub.png" /> <img src="//html.hanspub.org/file/20-2270679x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性支气管炎(CB)是一种慢性非特异性炎症，主要累及气管、支气管黏膜及其周围组织，临床症状以咳嗽、咳痰为主，每年发病持续3个月以上，连续2年或2年以上，排除具有咳嗽、喘息、咳痰、症状的其他疾病 [<xref ref-type="bibr" rid="hanspub.42802-ref1">1</xref>]。有统计显示，我国慢性支气管炎整体发病率约为3.8%，并随年龄升高而增长 [<xref ref-type="bibr" rid="hanspub.42802-ref2">2</xref>]，在50岁以上人群中的发病率上升到15% [<xref ref-type="bibr" rid="hanspub.42802-ref3">3</xref>]。慢性支气管炎致病因素与有害气体、有害颗粒、空气污染、病毒感染、免疫力低下、气候条件及年龄等密切相关，病程长，受到各类刺激因素易反复发作，发作时常咳痰明显、咳嗽剧烈、痰液黏稠偏黄伴随气喘等。一旦痰液过于黏稠，患者难以自主咳出，导致气道被堵塞，细菌附着痰液滋生，可能进一步引起气道感染、呼吸衰竭等并发症，甚至生命安全受到威胁 [<xref ref-type="bibr" rid="hanspub.42802-ref4">4</xref>]。若防治措施不得当，呼吸道粘膜分泌增加及支气管腺体的不断增生，反复炎症刺激损伤，引起气道重构，易发展为COPD，严重者可能会发生肺动脉高压，导致慢性肺源性心脏病 [<xref ref-type="bibr" rid="hanspub.42802-ref5">5</xref>]。因此有效控制缓解慢性支气管炎急性发作(以下简称“慢支急发”)具有十分重要的意义。本文通过对近年来中西医对慢性支气管炎的相关论文及报道的研读，总结其急性发作期发病机制及药物治疗概况如下。</p></sec><sec id="s6"><title>2. 中医病因病机</title><p>慢性支气管炎属中医的“咳嗽”、“喘证”、“痰饮”范畴，与肺、脾、肾三脏密切相关，外感六淫，内在脏腑功能失调、肺宣降失常、痰邪壅滞所致。历代医家对咳嗽的病因病机、治法等有论述 [<xref ref-type="bibr" rid="hanspub.42802-ref6">6</xref>]，《医方集解》为清代医家汪昂所著，书中有载：“久嗽有痰者，燥脾化痰，无痰者，清金降火。”清代程杏轩的《医述&#183;咳嗽》中谓：“肺金之虚，多由肾水之涸……是咳虽在肺，而实在肾。”现代医家在古代理论基础上，结合临床实践进行归纳和总结。杨月东等 [<xref ref-type="bibr" rid="hanspub.42802-ref7">7</xref>] 认为慢支发病有以下原因：一是因于风热、风燥、肝火犯肺，肺气宣发太过而咳；二是因痰饮或其他有形异物，致肺气不宣、气道壅滞不通，肺气冲逆而咳。三是肺病日久损耗肺阴，或患病日久累及肾，致肾不纳气、肺气肃降不及而咳；白云苹 [<xref ref-type="bibr" rid="hanspub.42802-ref8">8</xref>] 等采用现代统计方法，结合现代名老中医经验，分析得出，肺为慢性支气管炎主要病位，并涉及脾、肾和表、里，外感、内伤、痰、虚、寒、热等为其主要病因，主要病机为肺失宣肃、痰浊阻肺、痰热犯肺、气虚等。张辉等对366例慢支急发患者进行辨证总结，发现虚寒证、痰热证、痰湿证、肺燥证为主要分型 [<xref ref-type="bibr" rid="hanspub.42802-ref9">9</xref>]。肺、脾、肾三脏分别为“贮痰之器”、“生痰之源”、“生痰之本”，脏腑功能失调、痰邪壅滞导致本病。</p></sec><sec id="s7"><title>3. 西医病因、发病机制</title><p>现代医学认为，慢性支气管炎的发病主要与大气污染、粉尘、吸烟、感染、遗传等因素有关。支气管粘膜受到大气污染以及燃料烟尘、煤尘等粉尘刺激，引起肺纤维组织增生，肺清除功能遭受损害，引起肺功能(FEV1/FVC)下降 [<xref ref-type="bibr" rid="hanspub.42802-ref10">10</xref>]，提高了呼吸道细菌感染的风险 [<xref ref-type="bibr" rid="hanspub.42802-ref11">11</xref>]。吸烟，尼古丁、烟尘等长期附着支气管上皮，引起纤毛变短，纤毛运动障碍，肺泡吞噬细胞的吞噬、灭菌作用减弱，以及引起后天囊性纤维化跨膜转导调节因子(CFTR)障碍，呼吸道粘液蓄积，分泌物增加，并能引起全身性氧化应激和炎症反应，支气管收缩痉挛，气道阻力增加 [<xref ref-type="bibr" rid="hanspub.42802-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref14">14</xref>]。呼吸道感染是慢性支气管炎急性发作的重要因素 [<xref ref-type="bibr" rid="hanspub.42802-ref15">15</xref>]，主要病原菌有肺炎链球菌 [<xref ref-type="bibr" rid="hanspub.42802-ref16">16</xref>]、流感嗜血杆菌和莫拉卡他菌等。人体感染病毒(乙型流感病毒、副流感病毒、呼吸道合胞病毒、鼻病毒等)，也会导致呼吸道上皮损害、继发细菌感染，进而引起本病急性发作。遗传也是慢性支气管炎易感发病因素之一。基质金属蛋白酶MMP9、MMP3和TIMP3 (基质金属蛋白酶组织抑制剂)基因多态性以及MMP3和MMP12单倍型，可能在患儿易感慢性支气管炎气道和肺损伤中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.42802-ref17">17</xref>]。瘦素受体基因Gln223Arg突变，可能抑制瘦素的生物学作用，进而影响慢性支气管炎疾病进展 [<xref ref-type="bibr" rid="hanspub.42802-ref18">18</xref>]。有研究显示，慢性支气管炎患者CFTR基因的T5-TG12单倍型的比例明显高于健康受试者和哮喘患者 [<xref ref-type="bibr" rid="hanspub.42802-ref19">19</xref>]。</p><p>气道炎症是慢性支气管炎的基本病理改变，所涉及到的多种炎性细胞及其相关物质，在慢支急性发作过程中发挥抗炎或促炎作用。肺泡巨噬细胞可通过释放生长因子和细胞外基质(ECM)组分，修复肺组织损伤 [<xref ref-type="bibr" rid="hanspub.42802-ref20">20</xref>]。研究发现，慢性支气管炎大鼠模型中，脂多糖介导激活巨噬细胞的丝裂原活化蛋白激酶 (MAPK)通路中的ERK and p38 MAPK，进而影响环氧合酶-2 (COX-2)、前列腺素-2 (PGE2)和转化生长因子-β(TGF-β)的产生 [<xref ref-type="bibr" rid="hanspub.42802-ref21">21</xref>]。采用杂交技术造成的部分巨噬细胞缺失的小鼠模型，与正常小鼠相比，气道炎症、粘液阻塞发病率增加，细胞因子(TNF-α, IL-5, IL-17)和趋化因子(MIP-2，MIP-CSF和KC)等含量水平升高 [<xref ref-type="bibr" rid="hanspub.42802-ref22">22</xref>]。慢支患者气道中性粒细胞数目显著增加，释放氧自由基、蛋白水解酶等，造成肺组织损伤，细菌繁殖和感染的反复发生。慢支反复急性发作，中心粒细胞受细菌感染进一步刺激活化，会释放中性粒细胞胞外诱捕网(NETs)，引起机体细胞NETs沉积，长期暴露髓过氧化物酶(MPO)等抗原组分，免疫耐受失衡，产生MPO-ANCA(抗中性粒细胞胞质抗体)，增加ANCA相关性小血管炎发生的风险 [<xref ref-type="bibr" rid="hanspub.42802-ref23">23</xref>]。</p><p>机体免疫应答的主要效应细胞之一—T细胞，当细菌、肺炎衣原体等入侵人体呼吸系统后，产生的抗原多肽与MHC-I类分子结合，形成MHC-I类分子/抗原复合物，T细胞会主动识别复合物并杀伤，以保护机体。Th1/Th2细胞失衡也是气道炎症发生的关键因素。细胞因子如肿瘤坏死因子-α、白细胞介素-8、IL-4、IL-6、IL-10、IL-12、IL-13等均在慢支急发过程中发生重要作用 [<xref ref-type="bibr" rid="hanspub.42802-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref25">25</xref>]，慢支患者支气管黏膜细胞的IL-4高表达，还会促进气道黏液高分泌 [<xref ref-type="bibr" rid="hanspub.42802-ref26">26</xref>]。气道黏液高分泌是慢支急发的重要病理机制之一，气道粘蛋白(MUC) 5AC和(MUC) 5B是重要标志物 [<xref ref-type="bibr" rid="hanspub.42802-ref27">27</xref>]。细菌感染刺激呼吸道，上皮细胞Toll样受体4 (TLR4)水平升高，引起气道粘蛋白(MUC) 5AC分泌增加 [<xref ref-type="bibr" rid="hanspub.42802-ref28">28</xref>]，TLR4表达增高还可能使炎症反应增加，呼吸衰竭风险增大 [<xref ref-type="bibr" rid="hanspub.42802-ref29">29</xref>]。另有研究 [<xref ref-type="bibr" rid="hanspub.42802-ref30">30</xref>] 基于现代代谢组研究方法探索烟雾诱导慢性支气管炎的发病机制，结果发现含溶血磷脂酸在内的11个潜在生物标记物，其中溶血磷脂与炎症有重要关系，具有生物学意义。</p><p>慢支急发反复发生，进一步发展，肺泡细胞耗氧量明显增加，体内产生大量自由基，脂质过氧化反应增强，机体抵抗力降低，细胞坏死和组织损伤加剧，气道重塑，肺功能进一步减退 [<xref ref-type="bibr" rid="hanspub.42802-ref31">31</xref>]，发展为COPD。</p></sec><sec id="s8"><title>4. 慢支急发中医药治疗</title><p>近年临床针对慢支急发的中医药治疗，多采用常规西医治疗 + 经典名方加减/中成药中西结合的方式，研究发现与单纯西医治疗相比，中西医结合治疗可以显著提高有效率、改善症状、改善炎症指标、缩短病程、降低复发率等。张才来 [<xref ref-type="bibr" rid="hanspub.42802-ref32">32</xref>] 等采用二陈汤合三子养亲汤加减治疗慢支急发21例，观察组治疗后临床总有效率明显高于对照组(P &lt; 0.05)，且与对照组相比，能明显缩短发热停止时间、咳嗽停止时间、喘息消失时间及肺部啰音消失时间。金瑞凡 [<xref ref-type="bibr" rid="hanspub.42802-ref33">33</xref>] 采用清金化痰汤加减治疗痰热郁肺型慢支急发，相比对照组，试验组患者症候积分显著降低，咳嗽、咳痰缓解时间显著缩短。冯焕珍 [<xref ref-type="bibr" rid="hanspub.42802-ref34">34</xref>] 等应用杏苏散加减治疗痰浊阻肺型慢支急发，治疗后与对照组相比，观察组喘息、咳嗽咳痰、哮鸣的中医证候积分及症状消失时间明显降低，总有效率明显升高(P &lt; 0.05)。王丽娟 [<xref ref-type="bibr" rid="hanspub.42802-ref35">35</xref>] 等临床运用麻杏石甘汤治疗慢支急发效果显著，可明显改善咳嗽、喘息、呼吸困难等症状。有研究采用射干麻黄汤治疗慢支急发患者，相比对照组，疗效明显提高，血清PCT、IL-6、hs-CRP等含量水平显著降低 [<xref ref-type="bibr" rid="hanspub.42802-ref36">36</xref>]。刘铁柱等 [<xref ref-type="bibr" rid="hanspub.42802-ref37">37</xref>] 观察小青龙汤加减治疗慢支急发临床效果，治疗后与对照组相比，观察组患者起效快，总有效率和肺功能各项指标明显升高，肺功能改善，复发率降低(P &lt; 0.05)。临床运用止嗽散和桑白皮汤加减治疗慢支急发均取得理想治疗效果 [<xref ref-type="bibr" rid="hanspub.42802-ref38">38</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref39">39</xref>]。另有研究表明，在常规西医治疗基础上，加用疏风解毒胶囊、银黄清肺胶囊、川贝枇杷胶囊等中成药，中西结合治疗慢支急发，可以明显改善症状、提高有效率、改善炎症指标、缩短病程 [<xref ref-type="bibr" rid="hanspub.42802-ref40">40</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.42802-ref42">42</xref>]。</p></sec><sec id="s9"><title>5. 慢支急发西医治疗</title><p>临床西医针对慢支急发主要是采用抗感染和化痰、止咳、平喘等对症治疗，能有效控制感染、缓解症状，但也存在抗生素滥用细菌耐药、多药联用不良反应等问题。</p><p>感染是导致慢支急发的重要原因，有针对性的予以患者抗感染治疗是保证疗效的关键，防治感染性疾病的药物主要为抗生素 [<xref ref-type="bibr" rid="hanspub.42802-ref43">43</xref>]，临床上用于治疗慢性支气管炎的抗生素主要有阿莫西林克拉维酸钾、阿奇霉素、左氧氟沙星、莫西沙星等。于元强 [<xref ref-type="bibr" rid="hanspub.42802-ref44">44</xref>] 采用不同给药方法将阿莫西林克拉维酸钾对慢支急发患者进行治疗，发现采用序贯疗法效果最好，总有效率高，且治疗费用低、住院时间短。研究显示，左氧氟沙星与阿奇霉素联合使用治疗慢支急发，与单独使用阿奇霉素相比，可以缩短呼吸困难、肺部啰音、咳嗽咳痰症状消失时间及体温复常时间，减少不良反应 [<xref ref-type="bibr" rid="hanspub.42802-ref45">45</xref>]。Antonio等采用氟喹诺酮类(莫西沙星)，短期5天治疗慢支急发，能缩短住院时间，促进康复 [<xref ref-type="bibr" rid="hanspub.42802-ref46">46</xref>]。</p><p>除抗生素外，根据症状，临床还给与化痰、舒张支气管平滑肌、抗氧化应激、免疫抑制调节剂等药物治疗。盐酸氨溴索可促进痰液排泄及分泌物溶解，减轻慢性支气管炎患者痰液量和咳嗽症状 [<xref ref-type="bibr" rid="hanspub.42802-ref47">47</xref>]。多索茶碱，可使支气管平滑肌快速地松弛，有效缓解病灶处的炎症反应 [<xref ref-type="bibr" rid="hanspub.42802-ref48">48</xref>]。乙酰半胱氨酸能够有效降低炎症反应、抗氧化，减轻氧化应激，改善患者的肺功能，控制炎症水平 [<xref ref-type="bibr" rid="hanspub.42802-ref49">49</xref>]。胸腺肽既能强效抑制慢性支气管炎患者的免疫因子变态性增强反应，又能刺激调节体液免疫功能下降的状态，恢复机体免疫平衡，发挥双向调节功效 [<xref ref-type="bibr" rid="hanspub.42802-ref50">50</xref>]。根据病情需要，临床还常将抗生素、化痰药、支气管扩张药等联合使用。刘树海 [<xref ref-type="bibr" rid="hanspub.42802-ref51">51</xref>] 采用氨溴索联合头孢呋辛钠治疗老年慢支急发86例，总有效率95.35%，高于单用头孢呋辛钠组(83.72%)，且能明显缩短各项症状缓解时间。李廷灿 [<xref ref-type="bibr" rid="hanspub.42802-ref52">52</xref>] 等应用复方甲氧那明联合孟鲁司特钠治疗慢性支气管炎患者200例，与常规治疗相比，有效缓解咳嗽、喘息、咳痰临床症状，缩短缓解时间，改善FVC、FEV1和PEF等指标(P &lt; 0.05)。有文献报道 [<xref ref-type="bibr" rid="hanspub.42802-ref53">53</xref>]，采用羧甲司坦口服液联合盐酸氨溴索注射液治疗慢性支气管炎，有效缓解改善咳痰、咳嗽、肺啰音等症状，缩短病程。有研究显示，氨溴索联合左氧氟沙星治疗慢性支气管炎，可有效改善患者的肺功能，使生活质量提升 [<xref ref-type="bibr" rid="hanspub.42802-ref54">54</xref>]。Mostafa [<xref ref-type="bibr" rid="hanspub.42802-ref55">55</xref>] 等采用Farcosolvin糖浆(氨溴索–茶碱–愈创甘油醚混合物)治疗慢支急发患者，与对照组相比，呼吸困难和咳嗽评分明显改善(P &lt; 0.05)。</p><p>目前临床西医治疗也存在抗生素滥用细菌耐药、多药联用不良反应等问题。抗生素是目前细菌感染的主要治疗手段，但长时间使用容易导致患者出现耐药性以及药物不良反应，影响治疗效果 [<xref ref-type="bibr" rid="hanspub.42802-ref56">56</xref>]。据《柳叶刀传染病》杂志报道，一带一路沿线国家亦同样受到细菌耐药性的严重困扰，新型“超级细菌”在印度、巴基斯坦被发现。超级细菌因含有NDM-1基因，对青霉素、头孢类、亚胺培南、美罗培南等抗生素均具有耐药性 [<xref ref-type="bibr" rid="hanspub.42802-ref57">57</xref>]。抗生素类对抗病毒感染效果不明显，已有的有效抗病毒药物，价格昂贵且伴有一定的副作用，在治疗病毒性疾病方面具有很大的局限性 [<xref ref-type="bibr" rid="hanspub.42802-ref58">58</xref>]。除控制感染外，临床治疗慢性支气管炎急性发作，还需配合以祛痰药物等，多类化学药物联用增加不良反应的发生风险。</p></sec><sec id="s10"><title>6. 小结</title><p>综合以上，慢性支气管炎中医病因主要为外感六淫、内伤脏腑、痰、虚、寒、热等，病机以肺宣降失常、痰邪壅滞等为主，急性发作期证型以虚寒证、痰热证、痰湿证、肺燥证为主，主要累及肺、脾、肾三脏。西医病因主要为感染、大气污染、吸烟等，基本病理基础是气道炎症，涉及多类炎性细胞及因子，如不能及时控制，反复发作，会导致气道重塑，气道阻塞，发展成为COPD，甚至呼吸衰竭，危害大。本文对近年慢性支气管急性发作的中西医发病机制进行分析、归纳总结，为该病的临床治疗提供更多依据和参考。目前急性发作期治疗以控制感染为主，但抗生素耐药问题已日益显露，多药联用的不良反应问题亦同时存在。中药辨证施治，无耐药风险，且不良反应少，中西医结合治疗可以显著提高有效率、改善症状、改善炎症指标、缩短病程、降低复发率等，为临床治疗慢性支气管炎提供了更多的路径与方法。</p></sec><sec id="s11"><title>基金项目</title><p>湖南省科技厅：湖南省经典名方工程技术研究中心(2018TP2034)。</p></sec><sec id="s12"><title>文章引用</title><p>高 尚,屈金艳,易小兰,李艳波,文复权,王 炜. 慢性支气管炎急性发作期发病机制及药物治疗研究进展Research Progress on Pathogenesis and Drug Therapy in Acute Episode of Chronic Bronchitis[J]. 中医学, 2021, 10(03): 420-426. https://doi.org/10.12677/TCM.2021.103059</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42802-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">朱婴. 中医药治疗慢性支气管炎的研究进展[J]. 中医临床研究, 2017, 9(25): 142-144.</mixed-citation></ref><ref id="hanspub.42802-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">倪晓红. 慢性支气管炎加强循证护理干预对患者生存质量影响分析[J]. 大家健康(下旬版), 2014(5): 240.</mixed-citation></ref><ref id="hanspub.42802-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">罗舒文, 高兴亮, 陈龙全, 杨昌邦, 周诗立, 李沿君, 牟艳林. 慢性支气管炎的中西医结合治疗进展[J]. 湖北民族学院学报(医学版), 2019, 36(1): 75-77.</mixed-citation></ref><ref id="hanspub.42802-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">毛静. 慢性支气管炎急性加重期的临床治疗分析[J]. 中国医药指南, 2019, 17(12): 125-126.</mixed-citation></ref><ref id="hanspub.42802-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">史国欣. 慢性支气管炎、慢性肺源性心脏病、COPD患者不同时期BNP、肺功能、动脉血气的变化情况分析[J]. 社区医学杂志, 2015, 13(11): 56-58.</mixed-citation></ref><ref id="hanspub.42802-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">史利卿, 马建岭, 杨凯, 季坤, 温绍惠, 林彬. 慢性咳嗽中医病因病机及证候学规律的认识与探讨[J]. 现代中医临床, 2017, 24(5): 1-5.</mixed-citation></ref><ref id="hanspub.42802-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">杨月东, 苏克雷, 沈建平. 从病因性质探讨咳嗽病中气机改变的机理[J]. 中医药导报, 2018, 24(16): 126-127+133.</mixed-citation></ref><ref id="hanspub.42802-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">白云苹, 李建生, 李庆磊, 马锦地, 李杭洁. 基于现代名老中医经验的慢性支气管炎病因病机及证素规律研究[J]. 中华中医药杂志, 2017, 32(11): 4921-4924.</mixed-citation></ref><ref id="hanspub.42802-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张辉. 慢性支气管炎急性发作期中医证候分布规律及慢支方防治慢性支气管炎机制的实验研究[D]: [硕士学位论文]. 合肥: 安徽中医药大学, 2015.</mixed-citation></ref><ref id="hanspub.42802-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Panigrahi, A. and Padhi, B.K. (2018) Chronic Bronchitis and Airflow Obstruction Is Associated with Household Cooking Fuel Use among Never-Smoking Women: A Community-Based Cross-Sectional Study in Odisha, India. BMC Public Health, 18, Article No. 924. &lt;br&gt;https://doi.org/10.1186/s12889-018-5846-2</mixed-citation></ref><ref id="hanspub.42802-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sturm, R. (2013) Theoretical Models for the Simulation of Particle Deposition and Tracheobronchial Clearance in Lungs of Patients with Chronic Bronchitis. Annals of Translational Medicine, 1, Article No. 3.  
&lt;br&gt;https://doi.org/10.3978/j.issn.2305-5839.2012.11.02</mixed-citation></ref><ref id="hanspub.42802-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Vamsee, R.S., Solomon, G.M., Dransfield, M.T. and Rowe, S.M. (2016) Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance. Clinics in Chest Medicine, 37, 147-158. &lt;br&gt;https://doi.org/10.1016/j.ccm.2015.11.003</mixed-citation></ref><ref id="hanspub.42802-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bennett, W.D., Henderson, A.G. and Donaldson, S.H. (2016) Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis. Annals of the American Thoracic Society, 13, S186-S190.</mixed-citation></ref><ref id="hanspub.42802-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hu, G.P., Zhou, Y.M., Hong, W., Tian, J., Hu, J., Peng, G.Y., et al. (2013) Development and Systematic Oxidative Stress of a Rat Model of Chronic Bronchitis and Emphysema Induced by Biomass Smoke. Experimental Lung Research, 39, 229-240. &lt;br&gt;https://doi.org/10.3109/01902148.2013.797521</mixed-citation></ref><ref id="hanspub.42802-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">尹珊. 慢性支气管炎的病因病理[J]. 社区医学杂志, 2011, 9(3): 70-71.</mixed-citation></ref><ref id="hanspub.42802-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Vandevelde, N.M, Tulkens, P.M., Diaz, I.Y., Verhaegen, J., Rodriguez-Villalobos, H., Philippart, I., et al. (2014) Characterisation of a collection of Streptococcus pneumoniae Isolates from Patients Suffering from Acute Exacerbations of Chronic Bronchitis: In Vitro Susceptibility to Antibiotics and Biofilm Formation in Relation to Antibiotic Efflux and Serotypes/Serogroups. International Journal of Antimicrobial Agents, 44, 209-217.  
&lt;br&gt;https://doi.org/10.1016/j.ijantimicag.2014.05.016</mixed-citation></ref><ref id="hanspub.42802-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Korytina, G.F., Akhmadishina, L.Z., Viktorova, E.V., Tselousova, O.S., Danilko, K.V., Kochetova, O.V., et al. (2013) Extracellular Matrix Remodeling Genes Polymor-phisms and Risk of Chronic Bronchitis and Recurrent Pneumonia in Children. Journal of Human Genetics, 58, 467-474. &lt;br&gt;https://doi.org/10.1038/jhg.2013.24</mixed-citation></ref><ref id="hanspub.42802-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, B.L., Fu, E.Q., Cao, Y.Z., Zhong, Y.X., Fu, G.Q., Tian, X.X., et al. (2013) Effect of Leptin Receptor Mutation on the Development of Chronic Bronchitis. Asia Pacific Journal of Public Health, 25, 80-87.  
&lt;br&gt;https://doi.org/10.1177/1010539513497218</mixed-citation></ref><ref id="hanspub.42802-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P., Naruse, S., Yin, H., Yu, Z.F., Zhuang, T.Q., Ding, W., et al. (2012) The Susceptibility of T5-TG12 of the CFTR Gene in Chronic Bronchitis Occurrence in a Chinese Population in Jiangsu Province, China. The Journal of Biomedical Research, 26, 410-417. &lt;br&gt;https://doi.org/10.7555/JBR.26.20120015</mixed-citation></ref><ref id="hanspub.42802-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">葛金芳, 李俊, 姚宏伟. 慢性支气管炎免疫病理机制的研究进展[J]. 安徽医药, 2003, 7(3): 163-166, 175.</mixed-citation></ref><ref id="hanspub.42802-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y., Gao, J., Meng, X.M., Jiang, G.L., Yang, Y.R., Li, H, et al. (2011) Involvement of Mitogen-ACTIVATED protein Kinase Activation in Cyclooxygenase-2 and Transforming Growth Factor-β Production in Alveolar Macrophage from Chronic Bronchitis Rats. Immunopharmacology and Immunotoxicology, 33, 645-651.  
&lt;br&gt;https://doi.org/10.3109/08923973.2011.557383</mixed-citation></ref><ref id="hanspub.42802-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Saini, Y., Lewis, B.W., Yu, D.F., Yu, D., Dang, H., Livraghi-Butrico, A., et al. (2018) Effect of LysM+ Macrophage Depletion on Lung Pathology in Mice with Chronic Bronchitis. Physiological Reports, 6, e13677.  
&lt;br&gt;https://doi.org/10.14814/phy2.13677</mixed-citation></ref><ref id="hanspub.42802-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">范明华, 张铭, 梁晔, 邵世宏, 赵鹏, 苗玉, 邢广群. 大鼠慢性肺部感染刺激抗中性粒细胞胞质抗体产生及其机制[J]. 中华肾脏病杂志, 2019, 35(8): 603-610.</mixed-citation></ref><ref id="hanspub.42802-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">刘秀华. 慢性支气管炎的免疫病理机制及药物治疗[J]. 中国医药指南, 2010, 8(13): 197-198.</mixed-citation></ref><ref id="hanspub.42802-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">甘学军, 汪小华, 胡刚. 慢性支气管炎急性发作期患者血清肿瘤坏死因子α、白介素6水平变化及其临床意义[J]. 实用心脑肺血管病杂志, 2016, 24(5): 127-128.</mixed-citation></ref><ref id="hanspub.42802-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, J., Qiu, Y., Valobra, M., Qiu, S., Majumdar, S., Matin, D., et al. (2007) Plasma Cells and IL-4 in Chronic Bronchitis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 175, 1125-1133. &lt;br&gt;https://doi.org/10.1164/rccm.200602-161OC</mixed-citation></ref><ref id="hanspub.42802-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kesimer, M., Ford, A.A., Ceppe, A., Radicioni, G., Cao, R., Davis, W., et al. (2017) Airway Mucin Concentration as a Marker of Chronic Bronchitis. New England Journal of Medicine, 377, 911-922.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa1701632</mixed-citation></ref><ref id="hanspub.42802-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">万宁, 张建勇, 唐凤鸣, 李永春, 张健, 陈德. TLR4在慢性支气管炎大鼠气道粘液高分泌中的作用及多粘菌素B干预的影响[J]. 西部医学, 2015, 27(12): 1780-1784.</mixed-citation></ref><ref id="hanspub.42802-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Pace, E., Ferraro, M., Giarratano, A., Cipollina, C. and Gjomarkaj, M. (2013) TLR4 Up-Regulation and Reduced Foxp3 Expression in Mechanically Ventilated Smokers with Obstructive Chronic Bronchitis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 10, 147-155. &lt;br&gt;https://doi.org/10.3109/15412555.2012.730565</mixed-citation></ref><ref id="hanspub.42802-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">任晓磊. 基于代谢组学的慢性支气管炎发病机理及岩白菜素作用机制研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2016.</mixed-citation></ref><ref id="hanspub.42802-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">黄亚林. 野菊花提取物对慢性支气管炎大鼠免疫功能、自由基水平及肺组织病理形态学的影响[J]. 中国社区医师(医学专业), 2012, 14(5): 6.</mixed-citation></ref><ref id="hanspub.42802-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">张才来, 曾宪辉, 贾龙睿, 钟伟, 杨志武. 二陈汤合三子养亲汤加减治疗慢性支气管炎急性发作21例[J]. 基层医学论坛, 2019, 23(17): 2472-2474.</mixed-citation></ref><ref id="hanspub.42802-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">金瑞凡. 清金化痰汤加减治疗痰热郁肺型慢性支气管炎急性发作期的临床效果观察[J]. 中外医学研究, 2019, 17(8): 31-32.</mixed-citation></ref><ref id="hanspub.42802-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">冯焕珍, 区晓芬, 区晓珊. 杏苏散加减治疗痰浊阻肺型慢性支气管炎急性发作期的疗效观察[J]. 齐齐哈尔医学院学报, 2019, 40(16): 2033-2034.</mixed-citation></ref><ref id="hanspub.42802-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">王丽娟, 王明杰, 孙中莉, 黄亚会, 王飞. 麻杏石甘汤治疗慢性支气管炎急性发作临床研究[J]. 中国中医药现代远程教育, 2017, 15(21): 72-73.</mixed-citation></ref><ref id="hanspub.42802-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">刘颖慧. 射干麻黄汤对慢性支气管炎急性发作老年患者血清IL-6、PCT、hs-CRP的影响[J]. 中医药临床杂志, 2019, 31(6): 1108-1110.</mixed-citation></ref><ref id="hanspub.42802-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">刘铁柱, 龚泳梅. 小青龙汤加减治疗慢性支气管炎急性发作期临床疗效观察[J]. 中医临床研究, 2019, 11(5): 30-31+33.</mixed-citation></ref><ref id="hanspub.42802-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">豆卫卫. 桑白皮汤加减治疗慢性支气管炎急性发作的临床有效率分析[J]. 世界最新医学信息文摘, 2018, 18(A0): 157.</mixed-citation></ref><ref id="hanspub.42802-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">刘陈. 止嗽散加减治疗慢性支气管炎急性发作60例临床疗效观察[J]. 世界最新医学信息文摘, 2019, 19(30): 310.</mixed-citation></ref><ref id="hanspub.42802-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">费玲, 赵秋良, 张维维. 疏风解毒胶囊对风热犯肺型慢性支气管炎急性发作患者的影响[J]. 世界中医药, 2020, 15(22): 3439-3442.</mixed-citation></ref><ref id="hanspub.42802-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">范伏元, 柳玉佳. 银黄清肺胶囊联合阿莫西林克拉维酸钾治疗慢性支气管炎急性发作30例[J]. 中国中医药现代远程教育, 2013, 11(19): 71-72.</mixed-citation></ref><ref id="hanspub.42802-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">张秀玲, 姚晓轶. 川贝枇杷胶囊联合头孢哌酮治疗慢性支气管炎急性发作的临床研究[J]. 现代药物与临床, 2020, 35(11): 2243-2246.</mixed-citation></ref><ref id="hanspub.42802-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Sethi, S. (2010) Antibiotics in Acute Exacerbations of Chronic Bronchitis. Expert Review of Anti-Infective Therapy, 8, 405-417. &lt;br&gt;https://doi.org/10.1586/eri.09.133</mixed-citation></ref><ref id="hanspub.42802-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">于元强. 阿莫西林克拉维酸钾不同给药方法(序贯疗法、静脉滴注)对老年慢性支气管炎急性发作的治疗价值分析[J]. 临床医药文献电子杂志, 2019, 6(45): 25-26.</mixed-citation></ref><ref id="hanspub.42802-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">童细荣. 阿奇霉素联合左氧氟沙星治疗慢性支气管炎急性发作的临床疗效[J]. 临床合理用药杂志, 2019, 12(9): 60-61.</mixed-citation></ref><ref id="hanspub.42802-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Anzueto, A. and Miravitlles, M. (2010) Short-Course Fluoroquinolone Therapy in Exacerbations of Chronic Bronchitis and COPD. Respiratory Medicine, 104, 1396-1403. &lt;br&gt;https://doi.org/10.1016/j.rmed.2010.05.018</mixed-citation></ref><ref id="hanspub.42802-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">盛楠. 盐酸氨溴索治疗慢性支气管炎急性发作的疗效观察[J]. 中国医药指南, 2019, 17(14): 205-206.</mixed-citation></ref><ref id="hanspub.42802-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">王娜. 沐舒坦与多索茶碱结合对老年慢性支气管炎急性发作患者的疗效分析[J]. 中国医学工程, 2018, 26(7): 92-94.</mixed-citation></ref><ref id="hanspub.42802-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">谭强. 乙酰半胱氨酸治疗慢性支气管炎急性发作期患者的临床疗效观察[J]. 中国现代药物应用, 2019, 13(11): 118-119.</mixed-citation></ref><ref id="hanspub.42802-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">谢文卓. 胸腺肽联合抗生素治疗老年慢性支气管炎急性发作期疗效观察[J]. 现代诊断与治疗, 2017, 28(23): 4360-4361.</mixed-citation></ref><ref id="hanspub.42802-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">刘树海. 头孢呋辛钠联合氨溴索治疗老年慢性支气管炎急性发作临床分析[J]. 临床医药文献电子杂志, 2017, 4(68): 13406-13407.</mixed-citation></ref><ref id="hanspub.42802-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">李廷灿, 叶瑞航, 骆国勇. 孟鲁司特钠联合复方甲氧那明治疗慢性支气管炎效果分析[J]. 首都食品与医药, 2019, 26(21): 55-56.</mixed-citation></ref><ref id="hanspub.42802-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">朱应福. 盐酸氨溴索注射液联合羧甲司坦口服液治疗慢性支气管炎的疗效观察[J]. 心理月刊, 2019, 14(19): 179-180.</mixed-citation></ref><ref id="hanspub.42802-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">杨晓华. 左氧氟沙星联合氨溴索对慢性支气管炎患者肺功能及生活质量的应用观察[J]. 世界最新医学信息文摘, 2019, 19(29): 103-104.</mixed-citation></ref><ref id="hanspub.42802-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Yakoot, M., Salem, A. and Omar, A.-M. (2010) Clinical Efficacy of Farcosolvin Syrup (Ambroxol-Theophylline- Guaiphenesin Mixture) in the Treatment of Acute Exacerbation of Chronic Bronchitis. International Journal of Chronic Obstructive Pulmonary Disease, 5, 251-256. &lt;br&gt;https://doi.org/10.2147/COPD.S10981</mixed-citation></ref><ref id="hanspub.42802-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">黄坤, 刘正阳. 抗生素针对性用药治疗老年慢性支气管炎急性加重期的临床效果观察[J]. 临床合理用药杂志, 2019, 12(23): 52-53.</mixed-citation></ref><ref id="hanspub.42802-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">王逸飞. 浅谈超级细菌的耐药性及诊疗机制[J]. 临床医药文献电子杂志, 2016, 3(40): 8087-8088.</mixed-citation></ref><ref id="hanspub.42802-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">陈亚乔, 侯林, 崔清华, 刘相文, 袁琦, 张成华, 田景振. 中药抗病毒活性及作用机制研究进展[J]. 中医药导报, 2017, 23(22): 103-106.</mixed-citation></ref></ref-list></back></article>